Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06458439 · ClinicalTrials.gov registry record · Phase 2
Epcoritamab-CAR T Cells for Large B-cell Lymphomas
A Phase 2 study of Lymphoma, Non-Hodgkin and Refractory Diffuse Large B-Cell Lymphoma, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT06458439 is a Phase 2 study of Lymphoma, Non-Hodgkin and Refractory Diffuse Large B-Cell Lymphoma that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 31 participants, below the 394-participant average among 56 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06458439, a Phase 2 study of Lymphoma, Non-Hodgkin and Refractory Diffuse Large B-Cell Lymphoma, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
This study investigates the feasibility and efficacy of epcoritamab treatment before CAR T cells. This study also investigates if, when patients have residual lymphoma after CAR T cells, epcoritamab can help to effectively treat that lymphoma.
Conditions Studied
Interventions
- DRUG Epcoritamab
Study Locations (1)
Pennsylvania
- Abramson Cancer Center at the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2024-09-24 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06458439
The ClinicalTrials.gov registry entry for NCT06458439 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 394-participant average among 56 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (92% lower). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Lymphoma, Non-Hodgkin appearing as the primary indexed condition, and to 1 intervention - of which Epcoritamab is the first listed.
NCT06458439 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06458439 about?
NCT06458439 is a clinical study titled "Epcoritamab-CAR T Cells for Large B-cell Lymphomas". This study investigates the feasibility and efficacy of epcoritamab treatment before CAR T cells. This study also investigates if, when patients have residual lymphoma after CAR T cells, epcoritamab can help to effectively treat that lymphoma.
What is the current status of trial NCT06458439?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2024-09-24. Estimated completion is 2027-12.
What conditions does trial NCT06458439 study?
This clinical trial studies the following conditions: Lymphoma, Non-Hodgkin, Refractory Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma, Relapsed Diffuse Large B-cell Lymphoma, Transformed Indolent Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma.
What interventions are being tested in trial NCT06458439?
The interventions under investigation include: Epcoritamab (DRUG).
Who is sponsoring clinical trial NCT06458439?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06458439 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma, Non-Hodgkin
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RECRUITING · Phase 2
-
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
RECRUITING · Phase 2
-
Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)
ACTIVE NOT RECRUITING · Phase 2
-
Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)
COMPLETED · Phase 2
Explore more on PlainTrial
Lymphoma, Non-Hodgkin
All registered trials for this condition
Refractory Diffuse Large B-Cell Lymphoma
All registered trials for this condition
Pennsylvania
All trials with a study site in Pennsylvania
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.